DrugPatentWatch Database Preview
Drugs in Development Information for Imeglimin
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Imeglimin?
Imeglimin is an investigational drug.
There have been 6 clinical trials for Imeglimin.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2013.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Liver Diseases. The leading clinical trial sponsors are Poxel SA and [disabled in preview].
There are six US patents protecting this investigational drug and one hundred and forty-nine international patents.
Summary for Imeglimin
| US Patents | 6 |
| International Patents | 149 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-01-01) |
| Vendors | 17 |
Recent Clinical Trials for Imeglimin
| Title | Sponsor | Phase |
|---|---|---|
| Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects | Poxel SA | Phase 1 |
| Bioequivalence of Imeglimin Tablet Formulations | Poxel SA | Phase 1 |
| Effect of Cimetidine on the PK of Imeglimin | Poxel SA | Phase 1 |
Clinical Trial Summary for Imeglimin
Top disease conditions for Imeglimin
Top clinical trial sponsors for Imeglimin
US Patents for Imeglimin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Imeglimin | Start Trial | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | Start Trial |
| Imeglimin | Start Trial | Separation of triazine derivatives enantiomers using tartaric acid | Poxel (Lyons, FR) | Start Trial |
| Imeglimin | Start Trial | Biguanide compositions and methods of treating metabolic disorders | Elcelyx Therapeutics, Inc (San Diego, CA) | Start Trial |
| Imeglimin | Start Trial | Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization | Poxel (Lyons, FR) | Start Trial |
| Imeglimin | Start Trial | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | Start Trial |
| Imeglimin | Start Trial | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Imeglimin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Imeglimin | Argentina | 091089 | 2031-01-07 | Start Trial |
| Imeglimin | Argentina | 091739 | 2031-01-07 | Start Trial |
| Imeglimin | Australia | 2011317140 | 2030-10-19 | Start Trial |
| Imeglimin | Australia | 2011317143 | 2030-10-19 | Start Trial |
| Imeglimin | Australia | 2012204162 | 2030-10-19 | Start Trial |
| Imeglimin | Australia | 2012363873 | 2030-10-19 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
